Connection

David Turner to Humans

This is a "connection" page, showing publications David Turner has written about Humans.
Connection Strength

0.333
  1. Examination of the Effectiveness of the Healthy Empowered Active Lifestyles (HEAL) Program on Advanced Glycation End Products. Int J Environ Res Public Health. 2021 05 02; 18(9).
    View in: PubMed
    Score: 0.030
  2. Pubertal mammary development as a "susceptibility window" for breast cancer disparity. Adv Cancer Res. 2020; 146:57-82.
    View in: PubMed
    Score: 0.027
  3. Dietary advanced glycation end products and the risk of postmenopausal breast cancer in the National Institutes of Health-AARP Diet and Health Study. Cancer. 2020 06 01; 126(11):2648-2657.
    View in: PubMed
    Score: 0.027
  4. Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. Breast Cancer Res Treat. 2019 Feb; 173(3):559-571.
    View in: PubMed
    Score: 0.025
  5. The Role of Advanced Glycation End-Products in Cancer Disparity. Adv Cancer Res. 2017; 133:1-22.
    View in: PubMed
    Score: 0.022
  6. Advanced glycation end-products: a biological consequence of lifestyle contributing to cancer disparity. Cancer Res. 2015 May 15; 75(10):1925-9.
    View in: PubMed
    Score: 0.019
  7. AGE metabolites: a biomarker linked to cancer disparity? Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2186-91.
    View in: PubMed
    Score: 0.018
  8. ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype. Carcinogenesis. 2012 Mar; 33(3):572-80.
    View in: PubMed
    Score: 0.015
  9. Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression. Prostate. 2011 Dec; 71(16):1723-35.
    View in: PubMed
    Score: 0.015
  10. Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression. Mol Biol Cell. 2008 Sep; 19(9):3745-57.
    View in: PubMed
    Score: 0.012
  11. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev Anticancer Ther. 2008 Jan; 8(1):33-42.
    View in: PubMed
    Score: 0.012
  12. Defining ETS transcription regulatory networks and their contribution to breast cancer progression. J Cell Biochem. 2007 Oct 15; 102(3):549-59.
    View in: PubMed
    Score: 0.012
  13. Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res. 2007 Feb 15; 67(4):1618-25.
    View in: PubMed
    Score: 0.011
  14. The DNA N-glycosylase MED1 exhibits preference for halogenated pyrimidines and is involved in the cytotoxicity of 5-iododeoxyuridine. Cancer Res. 2006 Aug 01; 66(15):7686-93.
    View in: PubMed
    Score: 0.011
  15. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clin Microbiol Infect. 2022 Dec; 28(12):1649.e1-1649.e8.
    View in: PubMed
    Score: 0.008
  16. Dietary Advanced Glycation End-Products and Mortality after Breast Cancer in the Women's Health Initiative. Cancer Epidemiol Biomarkers Prev. 2021 12; 30(12):2217-2226.
    View in: PubMed
    Score: 0.008
  17. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021 04 10; 397(10282):1351-1362.
    View in: PubMed
    Score: 0.007
  18. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 03 06; 397(10277):881-891.
    View in: PubMed
    Score: 0.007
  19. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 01 09; 397(10269):99-111.
    View in: PubMed
    Score: 0.007
  20. Dietary Advanced Glycation End-products (AGE) and Risk of Breast Cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO). Cancer Prev Res (Phila). 2020 07; 13(7):601-610.
    View in: PubMed
    Score: 0.007
  21. BMI, physical activity, and breast cancer subtype in white, black, and Sea Island breast cancer survivors. Adv Cancer Res. 2020; 146:83-102.
    View in: PubMed
    Score: 0.007
  22. Hematopoietic stem cell-derived cancer-associated fibroblasts are novel contributors to the pro-tumorigenic microenvironment. Neoplasia. 2015 May; 17(5):434-48.
    View in: PubMed
    Score: 0.005
  23. Understanding the role of ETS-mediated gene regulation in complex biological processes. Adv Cancer Res. 2013; 119:1-61.
    View in: PubMed
    Score: 0.004
  24. MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer. Breast Cancer Res. 2013; 15(4):R70.
    View in: PubMed
    Score: 0.004
  25. Slug expression enhances tumor formation in a noninvasive rectal cancer model. J Surg Res. 2011 Sep; 170(1):56-63.
    View in: PubMed
    Score: 0.004
  26. Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF controls cell proliferation and mammary tumor progression. J Biol Chem. 2010 Apr 09; 285(15):11258-69.
    View in: PubMed
    Score: 0.003
  27. PDEF is a negative regulator of colon cancer cell growth and migration. J Cell Biochem. 2009 Dec 15; 108(6):1389-98.
    View in: PubMed
    Score: 0.003
  28. MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer. Cancer Res. 2008 Oct 15; 68(20):8499-506.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.